


Daclatasvir



Each triangle represents a manufacturer



Dossiers approved/filed



Companies planning to file



Companies filed



Companies approved

- Seven MPP licensees currently developing the two products, of which:
 - Four have filed with WHO-PQ
 - Three filings planned in 2019
- **Cipla, Hetero and Mylan** have received ERP approvals
- Currently approved in 16 countries and filed in another 30 countries


Approved (16)

Cambodia	Indonesia
Chad	Malawi
Congo	Mongolia
DR Congo	Myanmar
Ethiopia	Nicaragua
Gabon	Pakistan
Guyana	Turkmenistan
India	Uzbekistan

Filed (30)

Azerbaijan	Ghana	Rwanda
Benin	Guatemala	Senegal
Bolivia	Haiti	Sri Lanka
Botswana	Kenya	Sudan
Burkina Faso	Lao PDR	Suriname
Burundi	Namibia	Tanzania
Cameroon	Nepal	Uganda
Côte d'Ivoire	Nigeria	Vietnam
Dominican Republic	Paraguay	Zambia

Generic DAC has been filed in 46 countries, of which approval is received from 16



- Currently four MPP licensees are developing DAC/SOF combination, of which:
 - First filing with WHO-PQ is expected in Q3-18
 - Another three companies plan to file in the next year
- Currently approved in three countries and filed in another 14 countries